CHICAGO, May 3, 2024
/PRNewswire/ -- The latest product innovation by NICO
Corporation is described as a "game-changing advancement" by
neurosurgeons with early experience using the NICO Myriad SPECTRA
System – the ONLY hand-held technology delivering blue
excitation light to enhance tissue fluorescence and assist in the
rapidly growing sector of fluorescence-guided surgical removal of
grade III and IV glioma brain tumors.
New NICO SPECTRA is only hand-held
technology delivering blue light closer to target to enhance tissue
fluorescence.
"The SPECTRA was able to illuminate and provide enhanced
fluorescence better than ever before to a deep tumor through a very
small corridor," said Analiz Rodriguez, MD, PhD, director of
Neurosurgical Oncology and associate professor in the Department of
Neurosurgery at the University of
Arkansas for Medical Sciences (UAMS), who used a Minimally
Invasive Parafascicular Surgery (MIPS) approach with the NICO
BrainPath and SPECTRA System. "Sending light deep into the brain is
not easy and can make these cases extremely difficult. With
SPECTRA, I could more easily see the tumor because of enhanced
fluorescence. I know this will be a game changer for surgeons
striving to increase extent of resection, with the intent to
positively impact patient's lives."
The blue and white light from SPECTRA is mounted to NICO's
resection handpiece, enabling directional light closer to the area
of interest. Additionally, SPECTRA enables the unique ability for
the neurosurgeon to choose intensity levels for white and blue
light independently. The neurosurgeon can then easily toggle
between white and blue light with no need to shift focus from the
surgical field.
"The added visualization now possible when using SPECTRA is
remarkable," said Ranjeev Bhangoo,
MD, clinical director for Neuroscience at King's College Hospital
in London. "As a supplement to our
surgical microscope's blue light, we can see enhanced fluorescence
that was not observable before. It's a game-changing advancement to
aid fluorescence-guided surgery for high-grade glioma brain
tumors."
The SPECTRA System provides illumination, resection, collection
and biological preservation of tissue for the surgical removal of
brain tumors and intracerebral hemorrhages using minimally invasive
and open craniotomy surgical approaches. The technology is being
featured at the American Association of Neurosurgical Surgeons
(AANS) Annual Scientific Meeting that begins today in Chicago. Exclusive one-on-one demos using the
SPECTRA System are available at the NICO Booth #825 May 3-5 by appointment here.
Grade III or IV gliomas are the most frequent and fatal type of
brain tumors, with approximately 20,000 diagnoses
annually1 in the U.S. and 1.2 million
worldwide2. They are highly infiltrative and aggressive
tumors, commonly surgically removed with the aid of
fluorescene-guided agents to achieve the goal of maximal safe
resection. SPECTRA helps address common challenges in
fluorescence-guided procedures, such as presence of shadows created
by instruments, magnification and focus settings of the microscope,
and patient positioning.
"For patients undergoing the surgical resection standard of care
for high-grade glioma brain tumors, our innovation offers an
opportunity for improved extent of resection – a better version of
the surgical gold standard of care," noted Jim Pearson, president and CEO of NICO
Corporation, the worldwide leader in minimally invasive
neurosurgery. "Published evidence over the last decade suggests
that fluorescence-guided surgery improves extent of resection and
patient outcomes, making the introduction of our SPECTRA technology
particularly significant."
The SPECTRA Light Source was recently cleared by the U.S. Food
and Drug Administration (FDA) and is also registered for sales and
clinical use with the Medicines and Healthcare products Regulatory
Agency (MHRA) in the United
Kingdom. Learn more about NICO technologies at
NICOneuro.com; follow us on LinkedIn and Twitter, view
surgical and patient videos on YouTube.
1StatPearls. National Institute of Health, National
Library of Medicine. 2024.
https://www.ncbi.nlm.nih.gov/books/NBK441874/#:~:text=In%20the%20United%20States%2C%20there,the%20least%20malignant%20brain%20tumors
2National Institute of Health, National Library of
Medicine. 2024.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094646/#:~:text=High%2Dgrade%20gliomas%20(HGG%3B,year%20%5B1%2C2%5D
Contact: Sue Goin
sue.goin@sapphire-com.com
317.402.8690
View original content to download
multimedia:https://www.prnewswire.com/news-releases/leading-academic-neurosurgeons-describe-new-nico-myriad-spectra-system-as-a-game-changing-advancement-in-surgical-removal-of-high-grade-glioma-brain-tumors-302135451.html
SOURCE NICO Corporation